E Cannabis-Centric Bio-Pharma Stocks Category Declined Almost 3% This Past Week

TM Editors' Note: This article discusses penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

Currently there is no index that tracks the stock performances of the 13 clinical-stage biopharmaceutical companies involved in the development of drugs using CBD and THC exclusively (i.e. are cannabis-centric companies) to fill out the entirety of their drug-development pipelines. As such, this article introduces our new Pure-Play Cannabis-Centric Biopharma Stocks Index so that, in turn, this category of stocks can be compared to the performance of stocks in the Canadian Licensed Producers category, the American Multi-State Operators category, the Conservative Pot Stocks category and the Ancillary Pot Stocks category to give an accurate overview of the cannabis stock sector.

The new Pure-Play Cannabis-Centric Biopharma Stocks Index (see list of constituents below) identifies the current pure-play clinical stage biopharmaceutical companies, the extent of their volatility (beta) and their areas of research and is presented in descending order of  their market capitalization:

1 2 3
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.